Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04030091
Recruitment Status : Completed
First Posted : July 23, 2019
Last Update Posted : April 1, 2021
Sponsor:
Collaborator:
Innovative Diabetes Treatment Studies LLC.
Information provided by (Responsible Party):
Sciema UG

Brief Summary:
This study is an open label, prospective, randomised comparative, single center study. In the present study, the impact of a 12-week pulsatile insulin infusion therapy (PIT) with Humulin R 100 from

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 1 Drug: 3 hours humulin R 100 IU/mL PIT Drug: 2 hours humulin R 100 IU/mL PIT Phase 4

Detailed Description:

During the screening visit the patient will arrive at the study site and written informed consent will be obtained. Inclusion and exclusion criteria will be controlled and blood will be drawn for HbA1c and safety parameters. A point of care treatment (POCT) pregnancy test will be conducted in women of childbearing age. Patient demographics and history will be collected and a physical examination will be performed. The patient will complete a QoL, the continous glucose monitoring (CGM) sensor will be placed and trained, and the schedules for the subsequent treatment visits will be made. Also, the randomization (2 h vs 3 h) will be performed.

During the initiation visit , a series of clinical assessments will be made to document the patient status with respect to secondary complications: sensory nerve perception thresholds (tuning fork and path tester), retinopathy (RetinaVue camera). An ECG will be conducted, and blood will be drawn for assessment of the efficacy parameters. Thereafter the pulsatile insulin infusion therapy (PIT) procedure will be initiated.

For each PIT procedure: a venous catheter will be placed into one superficial vein at one arm, which will be connected to the insulin infusion pump and a glucose infusion pump via a three-way connector. Endothelial function will be measured by means of the Vendys 2 device (manufacturer: endothelix). The blood glucose will be tested by means of a POCT meter and the CGM, and the PIT procedure will be started (10 pulses of 3 U of regular human insulin per hour). Blood glucose will be tested every 5 to 10 min and glucose infusion will be started once a drop in blood glucose is detected. Adjustment of glucose administration will be performed until a stable glucose value between 80 mg/dL to 160 mg/dL is reached. In parallel, endothelial function will be measured every 30 min. At the end of the PIT procedure, the venous catheter will be removed and the patient will be discharged until the next visit.

During all consecutive treatment visits the patient will arrive at the investigational site at the agreed time-point and information regarding potential adverse events will be collected. Vital signs will be measured and the PIT procedure will be performed as described. At visits V6 and V10 additional examinations (assessments of neuropathy and retinopathy, blood draws for efficacy parameters, diabetes treatment satifaction questionnaire (DTSQ) questionnaire) will be performed.

During the final Visit the assessments from baseline (ECG, physical examination, neuropathy assessments, retinopathy assessment, blood draws for all safety and efficacy parameters incl. messenger ribonucleic acid (mRNA) analysis) will be repeated. The patient will complete a final DTSQ questionnaire, which concludes the participation in the trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 1 arm of 2 hours pulsatile insulin infusion treatment vs. a second arm of 3 hours pulsatile insulin infusion treatment.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study for Evaluation of the Impact of Pulsatile Insulin Infusion Therapy on Vascular Function in Patients With Type 1 and Type 2 Diabetes Mellitus
Actual Study Start Date : September 6, 2019
Actual Primary Completion Date : October 19, 2020
Actual Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 3 hour pulsatile normal insulin infusion treatment
the pulsatile insulin infusion treatment will be applied for 3 hours once a week with 10 pulses of 3 U of humulin R 100 IU/mL insulin per hour
Drug: 3 hours humulin R 100 IU/mL PIT
PIT procedure: a venous catheter will be placed into one superficial vein at one arm, which will be connected to the insulin infusion pump and a glucose infusion pump via a three-way connector. Endothelial function will be measured by means of the Vendys 2 device. The blood glucose will be tested by means of a POCT meter and the CGM, and the PIT procedure will be started (10 pulses of 3 U of regular human insulin per hour). Blood glucose will be tested every 5 to 10 min and glucose infusion will be started once a drop in blood glucose is detected. Adjustment of glucose administration will be performed until a stable glucose value between 80 mg/dL to 160 mg/dL is reached. In parallel, endothelial function will be measured every 30 min. At the end of the PIT procedure, the venous catheter will be removed and the patient will be discharged until the next visit.

Experimental: 2 hour pulsatile normal insulin infusion treatment
the pulsatile insulin infusion treatment will be applied for 2 hours once a week with 10 pulses of 3 U of humulin R 100 IU/mL insulin per hour
Drug: 2 hours humulin R 100 IU/mL PIT
As described for the Intervention "3 hours of pulsatile insulin infusion (PIT) with humulin R 100 IU/mL", the treatment duration is just one hour less.




Primary Outcome Measures :
  1. Endothelial function [ Time Frame: 1 hour ]
    Impact of PIT on endothelial function before and one hour after the PIT initiation measured with the Vendys2 device


Secondary Outcome Measures :
  1. Renal function [ Time Frame: 13 weeks ]

    It will be assessed whether insulin resistance has improved or worsened over the course of the study.

    Measured laboratory parameters for renal function (GFR, creatinine, proteinurea)


  2. nerve function [ Time Frame: 13 weeks ]
    Sensory nerve function (pathtester, tuning fork). It will be assessed whether insulin resistance has improved or worsened over the course of the study.

  3. Retinopathy [ Time Frame: 13 weeks ]
    Retinopathy will be measured with the RetinaVue device. It will be assessed whether Retinopathy has improved or worsened over the course of the study.

  4. HbA1c [ Time Frame: 13 weeks ]
    metabolic control

  5. Insulin resistance [ Time Frame: 13 weeks ]
    For assessment of insulin resistance glucose, retinol-binding protein 4 (RBP4), angiopoetin2, adiponectin, interleukin 6 (IL-6), hsCRP, glucagon, insulin, c-peptide, and intact Proinsulin will be measured. Finally, it is assessed whether insulin resistance has improved or worsened over the course of the study.

  6. Diabetes treatment satisfaction questionnaire [ Time Frame: 13 weeks ]
    Eight questions about the patient´s satisfaction with the diabetes treatment. Answer possibilities range form 1 (very good) to 10 (very bad)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Informed consent obtained prior to any trial-related activities
  2. Male or female > 18 years
  3. Diagnosed with Type 1 or 2 Diabetes ≥ 2 years
  4. HbA1c <10%
  5. Nephropathy with GFR between 30 and 60 mL/min/1,73m2 or < 75 GFR together with proteinuria and/or elevated creatinine levels
  6. Patient is naïve to pulsatile insulin treatment

Exclusion Criteria:

  1. Patients participating in another investigational drug study
  2. Current or history of dialysis therapy
  3. Anemia with hemoglobin < 10 g/dL
  4. Unstable significant cardiovascular disease with admission to emergency room or hospital in last 45 days
  5. Patients with diagnosed renal failure from non-diabetic etiology
  6. Pregnancy or breast feeding
  7. Patient unwillingness to use a CGM device, or inability (with or without family assistance) to replace the sensor every two weeks on the study CGM device
  8. Drug or alcohol abuse
  9. Sexually active woman of childbearing age not practicing birth control by accepted methods
  10. Lack of compliance or other reason that in the discretion of the investigator precludes satisfactory participation in the study
  11. Any severe illness preventing participation in the study per protocol (in the discretion of the investigator)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04030091


Locations
Layout table for location information
United States, New York
NYC Research, Inc.
New York, New York, United States, 10455
Germany
Pfützner Science & Health Institute GmbH
Mainz, Rhineland-Palatinate, Germany, 55128
Sponsors and Collaborators
Sciema UG
Innovative Diabetes Treatment Studies LLC.
Investigators
Layout table for investigator information
Principal Investigator: Andreas Pfuetzner, Prof. Dr. Dr. Pfützner Science & Health Institute GmbH
Layout table for additonal information
Responsible Party: Sciema UG
ClinicalTrials.gov Identifier: NCT04030091    
Other Study ID Numbers: DCTI-PIT-001
First Posted: July 23, 2019    Key Record Dates
Last Update Posted: April 1, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin
Insulin, Globin Zinc
Insulin, Isophane
Hypoglycemic Agents
Physiological Effects of Drugs